EXTENDED TREATMENT WITH ANTITHYMOCYTE GLOBULIN (ATGAM) IN RENAL ALLOGRAFT RECIPIENTS
- 1 November 1979
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 28 (5) , 365-367
- https://doi.org/10.1097/00007890-197911000-00003
Abstract
Twenty renal allograft recipients were treated with antithymocyte globulin (ATGAM; ATG) for up to 16 wk in addition to azathioprine and prednisone, while 20 controls received no ATG. The ATG group showed a lower incidence of 1st rejection episodes during the 1st mo. after transplantation and also a better functional graft survival rate up to 2 yr after transplantation. Results in this early ATG trial were better than those in subsequent trials which used 14 day treatment regimens. Longer treatment should be re-examined.This publication has 3 references indexed in Scilit:
- ANTITHYMOCYTE GLOBULIN (ATGAM) IN RENAL ALLOGRAFT RECIPIENTSTransplantation, 1979
- MANUFACTURE OF ANTITHYMOCYTE GLOBULIN (ATGAM) FOR CLINICAL TRIALSTransplantation, 1979
- EFFECT OF ANTILYPHOCYTE-GLOBULIN POTENCY ON SURVIVAL OF CADAVER RENAL TRANSPLANTSThe Lancet, 1977